Single-dose radical cure of Plasmodium vivax: A step closer

The Lancet

Volumn 383, Issue 9922, 2014, Pages 1020-1021

  Price, Ric N ^a,b   Nosten, François ^c,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^d MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; PLACEBO; PRIMAQUINE; TAFENOQUINE; HEMOGLOBIN;

ANTIMALARIAL ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HOST RESISTANCE; HUMAN; LATENT PERIOD; LOW DRUG DOSE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; NOTE; PARASITE CLEARANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REINFECTION; RELAPSE; RODENT MALARIA; SINGLE DRUG DOSE; TREATMENT DURATION; ANEMIA; DEVELOPMENTAL DISORDER; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; HEMOGLOBIN BLOOD LEVEL; MALNUTRITION; MORBIDITY; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; SPONTANEOUS ABORTION;

AMINOQUINOLINES; ANTIMALARIALS; CHLOROQUINE; FEMALE; HUMANS; MALARIA, VIVAX; MALE;

EID: 84896488430     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62672-0     Document Type: Note

References (11)

1. Gething PW, Elyaz ar IR, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012; 6: e1814
2. White NJ. Determi nants of relapse periodicity in Plasmodium vivax malaria Malar J 2011; 10: 297
3. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77 (suppl): 79-87
4. Howes RE, Piel FB , Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med 2012; 9: e1001339
5. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004; 39: 1336-45
6. Peters W, Robinson BL, Milhous WK. The chemotherapy of rodent malaria LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasitol 1993; 87: 547-52
7. Walsh DS, Wilairatana P, Tang DB, et al. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 2004; 39: 1095-103
8. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2013; published online Dec 19. http://dx.doi.org/ 10.1016/S0140-6736(13)62568-4
9. John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 2012; 11: 280
10. Sutanto I, Tjahjono B, Basri H, et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia Antimicrob Agents Chemother 2013; 57: 1128-35
11. Price RN, Auburn S, Marfurt J, Cheng Q. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol 2012; 28: 522-29